These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 30359357)

  • 1. Preventing cardiovascular disease in New Zealand: making better use of statins but also tobacco control, changing the food supply and other strategies.
    Wilson N; Jones AC; Nghiem N; Blakely T
    N Z Med J; 2018 Oct; 131(1484):61-67. PubMed ID: 30359357
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polypill for Population-Level Primary Cardiovascular Prevention in Underserved Populations-A Social Epidemiology Counterargument.
    Cainzos-Achirica M; Bilal U
    Am J Med; 2020 Oct; 133(10):e541-e543. PubMed ID: 32442515
    [No Abstract]   [Full Text] [Related]  

  • 3. Polypills for primary prevention of cardiovascular disease.
    Chow CK; Meng Q
    Nat Rev Cardiol; 2019 Oct; 16(10):602-611. PubMed ID: 31150009
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polypill: Progress and Challenges to Global Use--Update on the Trials and Policy Implementation.
    Webster R; Rodgers A
    Curr Cardiol Rep; 2015 Dec; 17(12):121. PubMed ID: 26497041
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The need for wider and appropriate utilization of aspirin and statins in the treatment and prevention of cardiovascular disease.
    Hennekens CH; Schneider WR
    Expert Rev Cardiovasc Ther; 2008 Jan; 6(1):95-107. PubMed ID: 18095910
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Strengths and Limitations of Using the Polypill in Cardiovascular Prevention.
    Roy A; Naik N; Srinath Reddy K
    Curr Cardiol Rep; 2017 May; 19(5):45. PubMed ID: 28425033
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is a statin as part of a polypill the answer?
    Robinson JG
    Curr Atheroscler Rep; 2009 Jan; 11(1):15-22. PubMed ID: 19080723
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dispensing data captures individual-level use of aspirin for cardiovascular disease prevention, despite availability over-the-counter.
    Selak V; Gu Y; Rafter N; Crengle S; Kerr AJ; Bullen C
    N Z Med J; 2016 May; 129(1435):21-8. PubMed ID: 27355165
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of statins in the primary prevention of cardiovascular disease: a systematic review and economic analysis for Belgium.
    Neyt M; De Laet C; Van Brabandt H; Franco O; Ramaekers D
    Acta Cardiol; 2009 Feb; 64(1):1-10. PubMed ID: 19317290
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of age, gender, ethnicity, socioeconomic status and region on dispensing of CVD secondary prevention medication in New Zealand: the Atlas of Health Care Variation CVD cohort (VIEW-1).
    Kerr A; Exeter D; Hanham G; Grey C; Zhao J; Riddell T; Lee M; Jackson R; Wells S
    N Z Med J; 2014 Aug; 127(1400):39-69. PubMed ID: 25145366
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376,162 patients.
    Naderi SH; Bestwick JP; Wald DS
    Am J Med; 2012 Sep; 125(9):882-7.e1. PubMed ID: 22748400
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Primary prevention for cardiovascular diseases: can statins replace aspirin?
    Abdul Hadi M; Ming LC; Awaisu A
    Med Princ Pract; 2011; 20(6):584. PubMed ID: 21986022
    [No Abstract]   [Full Text] [Related]  

  • 13. A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk.
    Patel A; Cass A; Peiris D; Usherwood T; Brown A; Jan S; Neal B; Hillis GS; Rafter N; Tonkin A; Webster R; Billot L; Bompoint S; Burch C; Burke H; Hayman N; Molanus B; Reid CM; Shiel L; Togni S; Rodgers A;
    Eur J Prev Cardiol; 2015 Jul; 22(7):920-30. PubMed ID: 24676715
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multi-constituent cardiovascular pills (MCCP)--challenges and promises of population-based prophylactic drug therapy for prevention of heart attack.
    Jamieson MJ; Naghavi M
    Curr Pharm Des; 2007; 13(10):1069-76. PubMed ID: 17430169
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The cost-effectiveness of drug treatments for primary prevention of cardiovascular disease: a modelling study.
    Marshall T
    Eur J Cardiovasc Prev Rehabil; 2006 Aug; 13(4):523-8. PubMed ID: 16874140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of switching from different treatment regimens to a fixed-dose combination pill (polypill) in patients with cardiovascular disease or similarly high risk.
    Lafeber M; Spiering W; Visseren FL; Grobbee DE; Bots ML; Stanton A; Patel A; Prabhakaran D; Webster R; Thom S; Rodgers A;
    Eur J Prev Cardiol; 2017 Jun; 24(9):951-961. PubMed ID: 28436727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of fixed dose combination treatment on adherence and risk factor control among patients at high risk of cardiovascular disease: randomised controlled trial in primary care.
    Selak V; Elley CR; Bullen C; Crengle S; Wadham A; Rafter N; Parag V; Harwood M; Doughty RN; Arroll B; Milne RJ; Bramley D; Bryant L; Jackson R; Rodgers A
    BMJ; 2014 May; 348():g3318. PubMed ID: 24868083
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of a Multidrug Pill In Reducing cardiovascular Events (UMPIRE): rationale and design of a randomised controlled trial of a cardiovascular preventive polypill-based strategy in India and Europe.
    Thom S; Field J; Poulter N; Patel A; Prabhakaran D; Stanton A; Grobbee DE; Bots ML; Reddy KS; Cidambi R; Rodgers A
    Eur J Prev Cardiol; 2014 Feb; 21(2):252-61. PubMed ID: 23038750
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cholesterol, cholesterol-lowering agents/statins, and urologic disease: Part V--Statins versus aspirin for primary prevention, and the winner is...?
    Moyad MA; Merrick GS
    Urol Nurs; 2007 Apr; 27(2):166-8. PubMed ID: 17494461
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The 2016 Joint European Prevention Guidelines and the uses of polypills: Time to update the evidence.
    Webster R; Grobbee D; Rodgers A
    Eur J Prev Cardiol; 2020 Mar; 27(4):437-440. PubMed ID: 31446790
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.